SCHEMBL1633643

SCHEMBL1633643

Brc1ccc(OC2CCNCC2)c2nc(Nc3ccc(N4CCOCC4)cc3)ncc12

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 6/20 0.51
CCND1 P24385 5/20 0.51
CDK1 P06493 4/20 0.51
CCNB1 P14635 4/20 0.51
CCNE1 P24864 4/20 0.51
CDK2 P24941 4/20 0.51
JAK2 O60674 4/20 0.50
TBK1 Q9UHD2 3/20 0.50
LRRK2 Q5S007 2/20 0.50
IGF1R P08069 4/20 0.48
SYK P43405 2/20 0.47
CDK6 Q00534 1/20 0.47
TNK2 Q07912 2/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
JAK3 P52333 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633288 0.94 CDK4 (0.54) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL1633571 0.91 TBK1 (0.54) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL1634127 0.90 CDK4 (0.49) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL13498236 0.89 CDK4 (0.51) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL1634274 0.89 CDK4 (0.51) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL1633537 0.88 SYK (0.50) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL1633150 0.88 CDK4 (0.52) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL1632510 0.87 IGF1R (0.51) CCNE1CDK2JAK2IGF1RJAK1
SCHEMBL1633600 0.87 CDK4 (0.49) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL1633501 0.87 LRRK2 (0.51) CDK4CCND1CDK1CCNE1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed